I/ONTAK plus PD-1 checkpoint inhibitor pembrolizumab to be evaluated in solid tumor patients
University of Pittsburgh dose-ranging study expected to begin in the fourth quarter of 2022
Read more at prnewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
I/ONTAK plus PD-1 checkpoint inhibitor pembrolizumab to be evaluated in solid tumor patients
University of Pittsburgh dose-ranging study expected to begin in the fourth quarter of 2022
Read more at prnewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| CTXR | 1.0700 | +0.0500 | +4.90% |
| Citius Pharmaceuticals Inc | |||